RXRX
$6.95
Revenue | $26.08Mn |
Net Profits | $-95.68Mn |
Net Profit Margins | -366.82% |
Recursion Pharmaceuticals-a’s revenue jumped 158.19% since last year same period to $26.08Mn in the Q3 2024. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 80.91% jump in its revenue since last 3-months.
Recursion Pharmaceuticals-a’s net profit fell -2.86% since last year same period to $-95.68Mn in the Q3 2024. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 1.91% jump in its net profits since last 3-months.
Recursion Pharmaceuticals-a’s net profit margin jumped 60.16% since last year same period to -366.82% in the Q3 2024. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 45.78% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.35 |
EPS Estimate Current Year | -0.35 |
Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a 12.5% jump from last quarter’s estimates.
Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current year stand at -0.35.
Earning Per Share (EPS) | -0.34 |
Recursion Pharmaceuticals-a’s earning per share (EPS) jumped 20.93% since last year same period to -0.34 in the Q3 2024. This indicates that the Recursion Pharmaceuticals-a has generated 20.93% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-05-09 | -0.42 | -0.39 | 7.14% |
2024-08-08 | -0.4 | -0.4 | 0% |
2024-11-06 | -0.35 | -0.34 | 2.86% |